Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4
Interventions: phase 2A Chlorthalidone, phase 2A Spironolactone, phase 2A Chlorthalidone + Spironolactone, phase 2B Chlorthalidone LD + Spironolactone LD; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: ADHD, Cannabis Use Disorder
Interventions: Delayed-release, extended-release methylphenidate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 26 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnant HIV Positive Women
Interventions: Doula Support Intervention; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alcohol Use Disorder
Interventions: Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Havre de Grace, Maryland

Conditions: Glioma
Interventions: [18F]FMISO-PET with contrast-enhanced MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Knee Osteoarthritis
Interventions: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP; Drug
Lead sponsor: Nova Vita Laboratory; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions: Tacabrutideg, Sonrotoclax, Obinutuzumab, Transthoracic Echocardiography Test, Biospecimen Collection, Computed Tomography, Multigated Acquisition Scan; Drug · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Patient Discharge, Neurocognition, Baseline
Interventions: custom-created apps, neuropsychological testing, and clinical assessments; Diagnostic Test
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Tourette Syndrome
Interventions: SCI-110, Placebo; Drug · Other
Lead sponsor: Neurothera Labs Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alzheimer Disease, Dementia, Sleep Disturbance
Interventions: Non-Contact Sleep Quality Monitor System; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Survivorship, Meal Kit, Culinary Medicine
Interventions: Meal Preps, Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 25 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Placebo - Control, Experimental
Interventions: EXERCISE TRAINING WITH OR WITHOUT MEDICATION; Drug
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Aging, Depression, Cognitive Symptoms
Interventions: Depression Cognitive Training, Non-Specific Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation); Behavioral · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Biospecimen Collection, Oral nicotine pouches, Survey Administration; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Exogenous Ketosis
Interventions: Ketone supplementation, Carbohydrate; Dietary Supplement
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Norman, Oklahoma

Conditions: Post Traumatic Concerns
Interventions: Dyadic (Child-Parent) Yoga; Behavioral
Lead sponsor: Florida Atlantic University; Other
Eligibility: 3 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Atrial Fibrillation, Stroke
Interventions: Alert-based computerized decision support; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Edgewood, Kentucky • Boston, Massachusetts

Conditions: IBD (Inflammatory Bowel Disease), IBD, IBD - Inflammatory Bowel Disease
Interventions: Confocal Laser Endomicroscopy; Device
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: 2 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Arlington, Texas • Fort Worth, Texas

Conditions: Intestinal Stricture, Crohn Disease, NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy, Abdominal Pain
Interventions: NaviCam Patency Capsule; Device
Lead sponsor: AnX Robotica Corp.; Industry
Eligibility: 22 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Downers Grove, Illinois

Conditions: Dupuytren's Contracture
Interventions: Radiation Therapy; Radiation
Lead sponsor: Yale University; Other
Eligibility: 30 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Greenwich, Connecticut

Conditions: Type 1 Diabetes Mellitus, Exercise Physiology
Interventions: Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Metformin; Drug
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stroke, Occupational Therapy, Activities of Daily Living, Rehabilitation, Virtual Reality
Interventions: VALOR Home Exercise Program (HEP), Usual Care Treatment (UCT) Control; Device · Other
Lead sponsor: Barron Associates, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sleep
Interventions: Construction Virtual Reality Stress Challenges, No Construction Virtual Reality Stress Challenges; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 49 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder

BRIDGES: An HIV Doula Program

Combination Therapy for Alcohol Use Disorder

Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas

NANOVAE to Treat Knee Osteoarthritis (KOA)

Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

PACU Discharge Readiness

SCI-110 in the Treatment of Tourette Syndrome

Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease

Food Is Medicine In Survivorship (Foodiis-AYA): Examining The Feasibility And Acceptability Of A Remotely-Delivered Meal Kit And Culinary Medicine Program For Survivors Of Adolescent/Young Adult (AYA) Cancer

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)

Studying Different Ways of Using Oral Nicotine Pouches to Understand the Effect on Nicotine Delivery, Appeal, and Side Effects Among Adult Cigarette Smokers

The Effects of Ketone Supplements With Carbohydrates on Cycling Performance Above Lactate Threshold

Project Leo: Trauma-Informed Yoga for Preschool Children and Parents

Computerized Decision Support to Prevent Stroke in Atrial Fibrillation

Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD

NaviCam Patency Capsule to Verify Gastrointestinal Patency

DEPART Study at Yale

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations

Virtual Activities of Living for Occupational Rehabilitation

Assessing Construction Execution Under Sleep Impairment